- Home
- CYH vs LRMR Comparison
CYH vs LRMR Comparison
Compare CYH & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- LRMR
- Stock Information
- Founded
- CYH 1985
- LRMR N/A
- Country
- CYH United States
- LRMR United States
- Employees
- CYH N/A
- LRMR N/A
- Industry
- CYH Hospital/Nursing Management
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- LRMR Health Care
- Exchange
- CYH Nasdaq
- LRMR Nasdaq
- Market Cap
- CYH 410.5M
- LRMR 360.3M
- IPO Year
- CYH 1991
- LRMR N/A
- Fundamental
- Price
- CYH $4.11
- LRMR $4.28
- Analyst Decision
- CYH Hold
- LRMR Strong Buy
- Analyst Count
- CYH 8
- LRMR 7
- Target Price
- CYH $3.73
- LRMR $16.71
- AVG Volume (30 Days)
- CYH 2.6M
- LRMR 3.1M
- Earning Date
- CYH 10-23-2025
- LRMR 11-14-2025
- Dividend Yield
- CYH N/A
- LRMR N/A
- EPS Growth
- CYH N/A
- LRMR N/A
- EPS
- CYH 2.47
- LRMR N/A
- Revenue
- CYH $12,644,000,000.00
- LRMR N/A
- Revenue This Year
- CYH N/A
- LRMR N/A
- Revenue Next Year
- CYH $2.46
- LRMR N/A
- P/E Ratio
- CYH $1.67
- LRMR N/A
- Revenue Growth
- CYH 0.74
- LRMR N/A
- 52 Week Low
- CYH $2.24
- LRMR $1.61
- 52 Week High
- CYH $4.64
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- CYH 72.00
- LRMR 50.70
- Support Level
- CYH $4.07
- LRMR $3.87
- Resistance Level
- CYH $4.43
- LRMR $4.48
- Average True Range (ATR)
- CYH 0.20
- LRMR 0.29
- MACD
- CYH 0.12
- LRMR -0.01
- Stochastic Oscillator
- CYH 79.87
- LRMR 61.48
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.